Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy - Wikidata - wikimedia - TriplyDB

Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy

Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy

http://www.wikidata.org/entity/Q24606104

about

Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist Protection against Radiotherapy-Induced Toxicity New approaches to radiation protection Endothelial perturbations and therapeutic strategies in normal tissue radiation damage Harnessing the Microbiome to Enhance Cancer Immunotherapy The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2)A non-synonymous coding variant (L616F) in the TLR5 gene is potentially associated with Crohn's disease and influences responses to bacterial flagellin NCI's provocative questions on cancer: some answers to ignite discussion.The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance.Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.Establishment of a mouse model of 70% lethal dose by total-body irradiation.CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation.A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.Microbiota and their role in the pathogenesis of oral mucositis.Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities.Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades.Radioprotective Agents: Strategies and Translational Advances.Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro.Single-Dose Radiation-Induced Oral Mucositis Mouse Model.Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.Trial Watch: Anticancer radioimmunotherapy.Trial Watch: Toll-like receptor agonists for cancer therapy.Trial Watch: Radioimmunotherapy for oncological indications.Tissue-engineered oral mucosa to study radiotherapy-induced oral mucositis.The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.Monophosphoryl lipid a attenuates radiation injury through TLR4 activation.Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.A novel model of megavoltage radiation-induced oral mucositis in hamsters: Role of inflammatory cytokines and nitric oxide.Intein-mediated backbone cyclization of entolimod confers enhanced radioprotective activity in mouse models.

P2860

Q24282585-A42539A1-EFBE-4A32-87ED-E5046A6190CF Q24623979-9CD92196-F7C0-482A-A983-492C626AB650 Q26741273-79FDAC2D-DF6D-48F1-BD89-F80E6FA5F12C Q27005588-F791AA5F-5F69-43F1-88AD-56E9DCAE6344 Q27027572-310C447C-E217-4AD0-8736-E284E6791557 Q28088598-965CE48D-2A00-4E5A-BD22-439C3D5F2750 Q28548012-0186C030-1CCB-443B-89F8-FE2AC51E1B90 Q28730900-CF7E6D8C-ED53-43D3-A6B2-26B6EB62E24C Q34674879-453A4A2A-4B9C-4D67-AC51-A48C6BCBD2B3 Q35764401-DABF2864-6E40-47E6-B4D8-ED1B86D3A9B7 Q36135801-CB4B9E43-7E79-430D-85D4-AC929CE3E217 Q36194849-382D563B-EA39-4F80-96D2-17F513E9D663 Q36234051-F4C24CF3-12DA-4C43-BAF0-8E3D24EF2DDC Q36607439-E5617891-0B08-443E-ABF4-887BD90DCCA1 Q36771989-13B09D4F-75E3-4391-A03F-BCCAF35999E2 Q37060556-02B7FD01-EF18-4B03-9266-FA02C9E4015E Q37227202-C2A6F9BC-06E6-45FB-9982-6BB9154C3B4B Q37478775-7EE4C371-1220-4330-AF76-132E003C14F7 Q37718417-0F0B7F7E-8DC3-4A72-9150-ABE0A823DA2B Q38181186-D14B3CE5-80B6-40CE-BA82-B04ED2F2F6C2 Q38204739-D221E1A6-AAB0-4973-B887-5BC856DC68F1 Q38610456-1F339D1D-CB8A-4144-AE10-6D510E919E77 Q38710560-F5C5C7D9-8CF2-4279-AF16-FC992BA4DC1C Q38838350-23E92E2E-6976-468F-86EF-ED8A74B080D6 Q41824143-5433273C-BE41-48CB-BF39-8673F91D1C1C Q41992352-AA488E43-9CD5-43A2-B04A-CF45F1B4C9E0 Q42847992-AFC96A6F-E899-4ABA-A255-11C6CABCD05E Q42969291-17418BD6-2740-414B-AD14-932F0EA5EF02 Q43104064-3C0EADEC-ED5B-4156-8D6E-5AF92998B31A Q46105730-DB89875E-7FFA-483E-9A54-F0ACBF1A3AA9 Q47125123-5148B31C-00B5-491C-A58C-1F0845B29610 Q47134893-3900B4E8-D249-41D2-8DEE-0A909479E119 Q50785469-3678B686-23E4-4765-A4FF-C37EA2654ECB Q51744174-01C9A201-C878-4541-9D82-B4314D1F8934 Q55285439-E013AF89-2C7D-418E-A849-6E519CDDE6B9

P2860

Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy

http://www.wikidata.org/entity/Q24606104

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@ast

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@en

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@nl

type

label

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@ast

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@en

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@nl

prefLabel

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@ast

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@en

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@nl

P1433

Q24606104-2E4371F7-C0EA-46CD-B367-0E8A221F5108

P1476

Q24606104-D974CDAF-550E-4135-BDAC-1E4CBFF2AD1B

P2093

Q24606104-3042CFE2-369A-4A05-AC9B-A566B2FED3E7

Q24606104-4EA3EAD2-0D38-47F5-8966-37637C76FDF4

Q24606104-672EF22A-AB1C-4030-905F-E04C079B60A1

Q24606104-67DC5A14-A3FB-439B-BC56-EE7E25F0C1F5

Q24606104-7519A748-8BC9-48A5-B2CD-6D22A05DCFB6

Q24606104-97C9D5DD-757D-422C-8025-55439E1B621E

Q24606104-99CDAC1F-F7EF-4709-8AD4-8FB1B96A804B

Q24606104-B775DD98-FD1E-42D2-A1AB-EABBEEF77BE5

Q24606104-FB865F2D-797B-497B-8D71-61B950C01866

P2860

Q24606104-07F091C0-89CC-4FB3-9EBF-A0579D577353

Q24606104-09005142-7C54-49E5-9984-FBF719FF9A29

Q24606104-3AEC283D-2265-4827-909F-16D6FAAC755E

Q24606104-6B9DED7D-FD54-4AFB-996D-B0DD751F4497

Q24606104-7DD67DB1-D216-4937-BD55-98D9BDC2EFAF

Q24606104-A61D1F7E-F78D-44AC-8AB1-FA2A2E13FD71

Q24606104-A8B8C447-B64B-40C5-9637-C1DED7FC5751

Q24606104-AEB1058A-12CB-434B-B1BC-8E40D23F1ED2

Q24606104-B13FC934-1CA7-4705-9115-DD0B501F5B1A

Q24606104-D16D4171-68C7-4C19-862D-B2B563ECE7E2

P304

Q24606104-0AB2A587-A9FB-4CCE-8524-29C80BE8F3A7

P31

Q24606104-3268E781-CF24-4C87-B025-7C8106D5755E

P3181

Q24606104-D0FCA19E-CAC0-44F2-9866-067CDD6A7ED2

P356

Q24606104-BEBA41C5-3B37-49BD-B449-28EDD18AB5E0

P407

Q24606104-23EF457E-CDE2-42A0-8588-F40B95D9A4BB

P433

Q24606104-31F3AD81-A2C8-4E69-8F9D-DD635207F67A

P478

Q24606104-41E9807D-3102-4EE5-9B8E-E52E0DF30124

P50

Q24606104-5DB27D0F-C734-45CE-82DE-00CAA5F407BC

P577

Q24606104-ADE68B9B-F90B-4890-AA95-02CFEB5BF835

P5875

Q24606104-959AE635-05AC-4741-A11B-5A7942A27C48

P698

Q24606104-5FA12F43-C78A-4A5F-87C1-2933E847F779

P921

Q24606104-88E45997-C283-4BF0-98E8-7AA1D4BCEEC8

Q24606104-F03EAD7B-8566-41FE-AC3F-A034A9B12EBC

P932

Q24606104-5D5501F7-9EA4-4CC1-B762-9524C4FC7CE0

P3181

P356

J.IJROBP.2011.05.055

P1433

International Journal of Radiation Oncology Biology Physics

P1476

Toll-like receptor 5 agonist p ...... d-and-neck cancer radiotherapy

@en

P2093

Anatoli S Gleiberman

http://www.w3.org/2001/XMLSchema#string

David Bellnier

http://www.w3.org/2001/XMLSchema#string

Elena Feinstein

http://www.w3.org/2001/XMLSchema#string

Ilia Toshkov

http://www.w3.org/2001/XMLSchema#string

Lyudmila G Burdelya

http://www.w3.org/2001/XMLSchema#string

Meghana Bapardekar

http://www.w3.org/2001/XMLSchema#string

Patricia Manderscheid-Kern

http://www.w3.org/2001/XMLSchema#string

Semra Aygun-Sunar

http://www.w3.org/2001/XMLSchema#string

Vadim I Krivokrysenko

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of radiation injuries: current approaches

Evidence-based skin care management in radiation therapy

Amifostine: the first selective-target and broad-spectrum radioprotector.

An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.

Prophylactic treatment reduces the severity of xerostomia following radiation therapy for oral cavity cancer.

Prevention and treatment of the consequences of head and neck radiotherapy.

Management of oral mucositis in patients who have cancer

Pharmacologic approaches to radiation protection.

Trends in the development of radioprotective agents.

Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.

P304

228-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

484996

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.IJROBP.2011.05.055

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Andrei V. Gudkov

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51718695

http://www.w3.org/2001/XMLSchema#string

P698

22000579

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

Toll-like receptor

P932

3261342

http://www.w3.org/2001/XMLSchema#string